Daiichi Sankyo Initiates Phase I Study to Evaluate the Combination Quizartinib and Milademetan

A first patient has been dosed in the first novel-novel combination phase I study evaluating two investigational agents being developed by Daiichi Sankyo. The phase I study will evaluate the...

Phase III ARCHES Trial Shows Positive Results for Enzalutamide in Prostate Cancer

Despite improved treatment options for patients progressing on standard hormone treatment, metastatic prostate cancer still remains a deadly disease. For men with metastatic hormone-sensitive prostate cancer (mHSPC), starting standard androgen...

Childhood Lymphoma Survivors have Elevated Risk of Solid Cancers

With new and advanced treatments, most children treated for various forms of lymphoma have the opportunity to survive into adulthood.  These patients are, however, at risk, for several possible...

Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics

Daiichi Sankyo and AnHeart Therapeutics, a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines, have entered into a worldwide exclusive license agreement to out-license...

Phase III AGENT Trial Enrolls First Metastatic Colorectal Cancer Patient

A first patient has been enrolled in the pivotal Phase III AGENT clinical study designed to evaluate arfolitixorin (Modufolin®; Isofol Medical) for the treatment of metastatic colorectal cancer (mCRC). The...

Jose Baselga Resigns as Co-Editor-in-Chief of Cancer Discovery

More than 100 days after the New York Times and ProPublica first revealed that Jose Baselga, MD, Ph.D, had failed to disclose millions of dollars in payments from industry,...